Pharmaceutical - Pharmaceutical, Newron Pharma


Popular Filters

Safinamide marketing application submitted to Swissmedic


Italian drug developer Newron Pharmaceuticals and its partner, family-owned Italian drugmaker Zambon…

Markets & MarketingNeurologicalNewron PharmaNorthern EuropePharmaceuticalRegulationsafinamideZambon

Patent expiries will push Parkinson’s drug market lower by 2019


Due to upcoming patent expirations for four high-profile drugs, the global Parkinson’s disease (PD)…

GlobalImpax LaboratoriesMarkets & MarketingNeurologicalNewron PharmaPatentsPharmaceuticalpimavanserinRytarysafinamide

Newron and Zambon file for EU approval of Parkinson’s drug safinamide


Italian drug developer Newron Pharmaceuticals and its partner, family-owned Italian drugmaker Zambon…

EuropeNeurologicalNewron PharmaNorth AmericaPharmaceuticalRegulationsafinamideZambon

Mixed results for AstraZeneca/B-MS' Onglyza; Newron's safinamide does well in PD


Anglo-Swedish drug major AstraZeneca (LSE: AZN) and US partner Bristol-Myers Squibb have announced mixed…

AstraZenecaBristol-Myers SquibbDiabetesNeurologicalNewron PharmaOnglyzaPharmaceuticalResearchsafinamideZambon

Flurry of M&A activity in Europe, with takeovers for NeuroNova and Proximagen


This morning saw a flurry of acquisition announcements by pharma companies. First up, Italy's Newron…

ApreaIndustrifondenKarolinska DevelopmentMergers & AcquisitionsNeuroNovaNewron PharmaOncopeptidesPharmaceuticalProximagenUpsher-Smith

Newron executes safinamide deal with Zambon; new Ph III data; management changes


In what was a busy news day for Italian drug developer Newron Pharmaceuticals SpA (SIX: NWRN), the company…

FinancialLicensingManagementNeurologicalNewron PharmaPharmaceuticalResearchsafinamideZambon

Newron licenses safinamide to Zambon for EU and USA


Italian drug developer Newron Pharmaceuticals (SIX: NWRN) says that it has signed a strategic collaboration…

LicensingMergers & AcquisitionsNeurologicalNewron PharmaPharmaceuticalsafinamideZambon

Newron updates on deal Meiji Seika Pharma deal; Almirall out-licenses in Korea


Italy’s Newron Pharmaceuticals (SIX: NWRN) yesterday said it has finalized a definitive license…

aclidiniumAlmirallAsia-PacificDaewoongLicensingMeiji Seika PharmaNeurologicalNewron PharmaPharmaceuticalRespiratory and Pulmonarysafinamide

Newron gets new partner for safinamide


Italy-headquartered R&D firm Newron Pharmaceuticals (SIX: NWRN) yesterday revealed that it has agreed…

Asia-PacificLicensingMeiji Seika PharmaNeurologicalNewron PharmaPharmaceuticalsafinamide

Newron says it has received interest in safinamide, rejected by Merck Serono


Following the announcement of Switzerland-based Newron Pharmaceuticals (SIX: NWRN) regaining the global…

LicensingNeurologicalNewron PharmaPharmaceuticalsafinamide

Repligen to buy Novozymes Biopharma Sweden business for $23 upfront; Biotie pulls out of Newron acquisition


USA-based Repligen (Nasdaq: RGEN) says it has signed a definitive agreement to acquire the business of…

Biotie TherapiesMergers & AcquisitionsNewron PharmaNovozymesPharmaceuticalRepligensafinamide

Merck returns safinamide rights to Newron; ImmuPharma regains Lupuzor from Cephalon


As part of the ongoing review and re-prioritization of its R&D pipeline, biotech firm Merck Serono, a…

BiotechnologyCephalonLicensingLupuzorMerck KGaAMerck SeronoNeurologicalNewron PharmaPharmaceuticalRare diseasessafinamideTeva Pharmaceutical Industries

Benefits of Biotie’s 45 million-euro buy of Newron assessed by Edison Research


Finland-based Biotie Therapies’ (OMX: BTH1V) proposed c 45 million-euro all-stock merger with Italian…

BiotechnologyBiotie TherapiesMergers & AcquisitionsNeurologicalNewron PharmaPharmaceuticalResearch

Back to top